Peptides for hair regrowth: separating hype from actual evidence

What did @metabolicblueprin actually say?

The creator named three peptides as the best options for hair regrowth: GHK-Cu (copper peptide), something they called "bioltenyl tripeptide one" (almost certainly biotinoyl tripeptide-1), and AHK-Cu. They described GHK-Cu as a "master signal peptide" that wakes up dormant follicles, claimed the body's levels drop "60% by the time you're 60," credited biotinoyl tripeptide-1 with improving hair anchoring and boosting eyebrow and lash density, and positioned AHK-Cu as the underdog that increases follicle size and promotes new blood vessel formation at the root. They closed with a reasonable caveat: poor nutrition, chronic inflammation, and stress will undercut any peptide protocol.

Worth noting: the creator mispronounced or misread biotinoyl tripeptide-1 as "bioltenyl tripeptide one" throughout. That's a minor presentation issue, but on a platform where viewers may try to source these compounds themselves, accuracy in naming matters.

Does the science back this up?

Partially, but the evidence base is thinner than the confident delivery implies. GHK-Cu has the strongest research footprint of the three, biotinoyl tripeptide-1 has cosmetic-grade data, and AHK-Cu evidence in humans is sparse.

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) has been studied since the 1970s. Pickart and Margolina (2018, Biomedicines) documented its role in wound healing, collagen synthesis, and anti-inflammatory signaling. A study by Uno and Kurata (1993, Journal of Investigative Dermatology) found topical copper peptides increased follicle size and hair density in animal models. Human data is more limited but exists: Finner (2013, Dermatologic Clinics) noted copper peptides show promise in androgenetic alopecia, though head-to-head trial data against established treatments like minoxidil is lacking.

Biotinoyl tripeptide-1 (also sold as Procapil) appears mostly in cosmetic formulation literature. Trüeb (2015, International Journal of Trichology) reviewed cosmetic peptides for hair, noting modest anchoring and follicle stimulation signals in in vitro and small clinical studies, but called the evidence base preliminary. The eyebrow and lash density claim the creator makes is plausible based on product studies, but independent peer-reviewed confirmation is thin.

AHK-Cu (alanine-histidine-lysine copper complex) has the weakest published record of the three. Most references originate from patent literature and manufacturer-funded work. Claiming it "forms new blood vessels at the root" as confidently as the creator does overstates what the peer-reviewed record actually supports at this point.

What did they get wrong (or right)?

The 60% decline figure for GHK-Cu deserves scrutiny. The creator states GHK-Cu levels "drop by 60% by the time you're 60." This number circulates widely in peptide content, and it traces back to Pickart's own work and subsequent reviews, but it refers to plasma GHK levels measured in aging populations, not a clean controlled longitudinal study. Treating it as a precise, settled statistic is overconfident. The directional claim, that GHK-Cu declines with age, is reasonable. The specific percentage should be presented with more uncertainty than the creator uses.

What they got right: the closing argument about foundations. "If you're under eating, you're protein deficient, or chronically inflamed... no peptide protocol is going to override that" is genuinely correct and rarely said in this content space. Hair follicles are metabolically expensive tissue. Nutrient deficiency and systemic inflammation are documented contributors to telogen effluvium and androgenetic alopecia progression. Credit where it's due, that's a responsible framing that most peptide creators skip entirely.

What they got wrong: presenting AHK-Cu with the same confidence as GHK-Cu. The evidence tiers are not equal, and the video doesn't signal that to viewers.

What should you actually know?

If you're considering any of these compounds, the regulatory and safety picture matters as much as the mechanism claims. GHK-Cu in topical form is available in cosmetic products and has a reasonable safety profile documented across decades of use. Injectable peptide formulations are a different category entirely, carrying different risk profiles and sitting in a regulatory gray zone in the United States, where many are compounded rather than FDA-approved drugs.

The creator does not distinguish between topical and injectable application routes, which is a real gap. A viewer who walks away thinking "I should get GHK-Cu" might be considering a cosmetic serum or a compounded injectable, and those are not equivalent decisions.

Hair loss also has multiple causes, including androgenetic alopecia, alopecia areata, thyroid dysfunction, iron deficiency, and medication side effects. Peptide content on TikTok almost never asks which type of hair loss the viewer has. A blanket peptide recommendation without knowing the underlying cause is not evidence-based practice. If you're experiencing significant hair loss, a dermatologist or trichologist who can actually diagnose the cause is the appropriate starting point, not a peptide stack.